Colesevelam

Summary

Colesevelam (CHEMBL6068331) is an approved unknown (ATC C10AC04); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: C10AC04
• Indications: 1 condition
• Clinical trials: 35

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068331
Name	Colesevelam
Type	Unknown
Max phase	4
ATC	C10AC04

Also known as: Colesevelam, COLESEVELAM

Parent form; salt/anhydrous children: CHEMBL1201473

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 35.

Phase distribution

Phase	Trials
PHASE4	15
PHASE2	8
PHASE3	4
Not specified	3
PHASE1/PHASE2	2
PHASE2/PHASE3	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00655265	PHASE4	COMPLETED	A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication
NCT00715273	PHASE4	COMPLETED	Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication
NCT00753779	PHASE4	COMPLETED	A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.
NCT00754039	PHASE4	COMPLETED	Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
NCT00754507	PHASE4	COMPLETED	A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.
NCT00951899	PHASE4	COMPLETED	The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
NCT01203254	PHASE4	TERMINATED	Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn’s Disease
NCT01239004	PHASE4	COMPLETED	Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
NCT01258075	PHASE4	COMPLETED	Colesevelam for Children With Type 2 Diabetes
NCT02050074	PHASE4	COMPLETED	The Role of Metformin and Colesevelam in Human GLP-1 Secretion
NCT02111603	PHASE4	COMPLETED	Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
NCT02682680	PHASE4	COMPLETED	Randomized Trial Comparing Colesevelam vs. Ezetimibe
NCT02876484	PHASE4	COMPLETED	Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
NCT02952963	PHASE4	COMPLETED	Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
NCT03955575	PHASE4	COMPLETED	Treatment of Bile Acid Malabsorption With Liraglutide
NCT00570739	PHASE3	COMPLETED	Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
NCT00756171	PHASE2/PHASE3	COMPLETED	Colesevelam Versus Placebo in Cholestatic Pruritus
NCT00789750	PHASE3	COMPLETED	Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
NCT00990184	PHASE3	COMPLETED	Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
NCT02628626	PHASE3	COMPLETED	A Study of Colesevelam in Fecal Incontinence
NCT05252988	PHASE2	ACTIVE_NOT_RECRUITING	Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
NCT07226440	PHASE1/PHASE2	RECRUITING	Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)
NCT07592858	PHASE2	NOT_YET_RECRUITING	Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study
NCT00147745	PHASE2	COMPLETED	Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
NCT00690937	PHASE2	COMPLETED	A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia
NCT00911612	PHASE2	COMPLETED	Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
NCT02619812	PHASE2	TERMINATED	Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
NCT03270085	PHASE2	COMPLETED	Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
NCT03767257	PHASE2	COMPLETED	A Study of Colesevelam for Lenalidomide-Associated Diarrhea
NCT06197763	PHASE1/PHASE2	UNKNOWN	Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.
NCT00692250	PHASE1	COMPLETED	A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers
NCT06925997	EARLY_PHASE1	RECRUITING	Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery
NCT01656057	Not specified	COMPLETED	The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
NCT01666223	Not specified	COMPLETED	Effect of Bile Acids on GLP-1 Secretion
NCT01948648	Not specified	UNKNOWN	Effects of Fish Oil and Colesevelam (STAIR7007)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).